Cvergenx

What Cvergenx does

Cvergenx is a privately held cancer molecular diagnostics company that provides biologically guided radiation therapy decision support. Its core offering, the precisionRT Dose (pRTD™) platform, integrates three proprietary genomic tools: the Radiosensitivity Index (RSI), a 10-gene expression biomarker that quantifies intrinsic tumor radiosensitivity; the Genomic Adjusted Radiation Dose (GARD) metric, which combines RSI with delivered radiation dose to predict clinical outcomes; and popGARD/RxRSI, which optimize patient- and population-specific dose selection. These tools sit under the company's broader Precision Genomic Radiation Therapy (pGRT™) platform. The company operates as a clinical laboratory service through a CLIA-certified lab at Moffitt Cancer Center in Tampa, Florida, serving radiation oncology departments, cancer treatment centers, and clinical trial sponsors. Validation spans 27 international studies and multiple tumor types including breast, lung, head and neck, pancreatic, and glioblastoma, and the SFRO 2025 guidelines classify RSI and GARD as Level II evidence.

Cvergenx was co-founded by physician-scientists Dr. Javier F. Torres-Roca (CEO, Moffitt/University of South Florida), Dr. Steven A. Eschrich (CTO, Moffitt/USF), and Dr. Jacob G. Scott (CSO, Cleveland Clinic), who are the named inventors on the RSI, GARD, and RxRSI patent families. The business model is genomic testing services delivered through the Moffitt CLIA-certified lab, with pricing negotiated via institutional contracts and insurance reimbursement; no public pricing is disclosed. Commercialization relies on a sales-led motion into academic medical centers and cancer treatment centers, supplemented by peer-reviewed publications in journals such as Lancet Oncology and Journal of Clinical Oncology and presentations at conferences including SFRO.

The company's footprint is small (1–10 employees, effectively three executives) and it has disclosed only a single seed round of $225,554 in 2010, indicating that growth to date has been funded largely through founder and academic resources. Key named relationships are Moffitt Cancer Center (strategic lab partner and founder home institution) and Cleveland Clinic (CSO affiliation). Recent clinical milestones include completion of a Phase II soft-tissue sarcoma trial (HEAT) validating GARD-based dose predictions, an ongoing Phase II trial in triple-negative breast cancer, and additional planned trials in HPV-associated oropharyngeal cancer.

Name

Cvergenx

Legal name

CvergenX

Website

https://cvergenx.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

1–10 employees

Short description

Cvergenx is a privately held cancer molecular diagnostics company operating a CLIA-certified lab at Moffitt Cancer Center, selling the precisionRT Dose (pRTD™) platform—built on the RSI biomarker and GARD metric—to personalize radiation therapy for oncology providers and clinical trial sponsors.

Ownership category

akta.pro rank

Product category

Radiation Oncology Diagnostics

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Companion Diagnostics (CDx) & Therapy Selection Assays (HLAAALAF)

akta.pro secondary industries

Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Radiation Dose Management & Analytics (HLACALAH), Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)

Keywords

• Radiation oncology diagnostics
• Genomic biomarker testing
• Tumor radiosensitivity analysis
• Precision radiation therapy
• Molecular cancer diagnostics

Headquarters

HQ city

Tampa

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Genomic Testing Services: Revenue generated from laboratory testing services analyzing tumor samples to calculate RSI and GARD scores for clinical decision support in radiation oncology treatment planning.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Cvergenx operates a CLIA-certified clinical laboratory that performs genomic testing of tumor samples to quantify intrinsic radiosensitivity and recommend personalized radiation doses. Its precisionRT Dose (pRTD™) platform — also branded as pGRT™ (Precision Genomic Radiation Therapy) — integrates the Radiosensitivity Index (RSI) gene-expression biomarker, the Genomic Adjusted Radiation Dose (GARD) metric, and popGARD/RxRSI optimization tools to enable biology-driven radiotherapy prescription for radiation oncologists treating cancer patients. The offering is delivered as a laboratory service through Moffitt Cancer Center to healthcare providers and cancer treatment centers.

Product overview

CvergenX offers a unified precision oncology platform centered on precisionRT Dose (pRTD™), which integrates three proprietary genomic tools—RSI (Radiosensitivity Index), GARD (Genomic Adjusted Radiation Dose), and popGARD/RxRSI—to enable biologically guided radiotherapy. RSI provides a gene-expression based radiosensitivity score; GARD translates this score into a personalized radiation dose recommendation; and popGARD/RxRSI offer population- and patient-specific dose optimization. The pGRT (Precision Genomic Radiation Therapy) platform encompasses these tools as clinical decision-support for radiation oncologists.

Differentiator

Problem solved

Functional benefit

Brands

• pGRT™ (Precision Genomic Radiation Therapy): Precision Genomic Radiation Therapy platform integrating patented genomic and mathematical models for radiation dose optimization
• precisionRT Dose (pRTD™)

Products and services

• precisionRT Dose (pRTD™) Platform / pGRT™ (Precision Genomic Radiation Therapy)

Quantifiable outcome

• GARD scores ranged from 15.4 to 71.7 in HPV+ oropharyngeal cancer patients receiving same physical radiation dose, demonstrating biological heterogeneity
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Partnerships

One partnership is on record.

• Moffitt Cancer CentercoreTechnology or IntegrationStrategic partnership for CLIA-certified laboratory operations where RSI/GARD testing is performed. The Moffitt Cancer Center houses the company's laboratory and is the academic home of founding scientists Dr. Javier Torres-Roca and Dr. Steven Eschrich. The partnership provides clinical validation infrastructure and institutional credibility for the precision oncology platform.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Guardant Health: Liquid biopsy and precision oncology company providing blood-based genomic profiling for therapy selection and disease monitoring. Comparable to Cvergenx as a cancer molecular diagnostics company with a strong companion diagnostics franchise (Guardant360 CDx), though Guardant's strength is in liquid biopsy rather than tumor tissue radiation biomarkers.
• Foundation Medicine: Roche-owned leader in comprehensive genomic profiling and companion diagnostics for oncology. Comparable to Cvergenx as a cancer molecular diagnostics company selling genomic tests that guide therapy selection, though Foundation Medicine's portfolio is much broader and not specialized in radiation dose optimization.
• Tempus AI: AI-driven precision medicine platform combining genomic sequencing, clinical data, and analytics to support oncology therapy decisions. Comparable to Cvergenx as a precision oncology decision-support company with lab services, though Tempus operates at much larger scale across multiple therapy areas beyond radiation oncology.
• Natera: Molecular diagnostics company offering Signatera for MRD monitoring and other oncology testing. Comparable to Cvergenx as a cancer molecular diagnostics company with proprietary assays sold to oncologists and academic centers, though Natera focuses on recurrence monitoring rather than radiation dose selection.
• Exact Sciences: Established molecular diagnostics company known for Cologuard, expanding into oncology therapy selection and MRD (Oncotype, Prevail). Comparable to Cvergenx as a publicly-traded oncology diagnostics player with established lab infrastructure and payer relationships, though Exact Sciences focuses on screening and recurrence monitoring rather than radiation biomarkers.
• NeoGenomics: Specialized oncology reference laboratory providing a broad menu of cancer diagnostic and monitoring tests, including biomarker testing for therapy selection. Comparable to Cvergenx as a CLIA-certified oncology lab service provider, though NeoGenomics offers a much broader test menu across community oncology rather than specializing in radiation biomarkers.

Others

• Agilent Technologies: Major life sciences tools and diagnostics company including companion diagnostics development (Resolution Bioscience acquisition). Comparable to Cvergenx as a participant in oncology companion diagnostics development and laboratory analytical instruments, though Agilent operates as a much broader platform rather than specializing in radiation biomarkers.

Direct peers

• Personalis: Cancer genomics company specializing in tumor profiling for therapy selection and minimal residual disease detection. Comparable to Cvergenx in oncology biomarker discovery and clinical-grade lab services, though Personalis focuses on immunotherapy and MRD rather than radiation dose optimization.
• Strata Oncology: Precision oncology company providing tumor molecular profiling to guide therapy selection and clinical trial enrollment. Closely comparable to Cvergenx in business model (tissue-based molecular profiling as a service for therapy decision support), serving similar academic and community oncology customers.
• Caris Life Sciences: Molecular profiling company offering multi-omic tumor profiling (MI Profile) and companion diagnostics to guide oncology treatment decisions. Highly comparable to Cvergenx in business model (oncology CDx lab services) and customer base (academic cancer centers), though Caris focuses on drug therapy selection rather than radiation dose optimization.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/cvergenx

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cvergenx